 |
부광약품부광약품(www.bukwang.co.kr)은 한국거래소에 상장된 국내 유수의 제약회사입니다[KRX:003000]. |
 |
BDD PharmaBDD Pharma Ltd (www.bddpharma.com) is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD’s OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, targeted release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents across a number of territories including the US, EU and Japan. Supported by investment from Archangels, the Scottish Investment Bank, Alderley Park Ventures and BioCity Investments, BDD has in-house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans. BDD’s SWIFT adaptive clinical trials integrate formulation development, GMP manufacturing and clinical testing into one streamlined service, offering a more flexible approach than the conventional clinical trial design structure. |
 |
University of Copenhagen – Dept. Drug Design and Pharmacology콘테라파마는 코펜하겐대학교 보건 및 의학 학부 (Faculty of Health and Medical Sciences at University |
Recent News
April 11, 2023
Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform
Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera…
Read more
September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
Contact us
콘테라파마 본사
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
